CA125 sensitivity for different stages of ovarian cancer, at a specificity of 0.9, was 0.81 for combined stages I and II, 0.86 for stage III, and 0.94 for stage IV (Figure 3). This evidence concerns the gene MUC16 and ovarian carcinoma.